JPWO2022032004A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022032004A5 JPWO2022032004A5 JP2023507973A JP2023507973A JPWO2022032004A5 JP WO2022032004 A5 JPWO2022032004 A5 JP WO2022032004A5 JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023507973 A JP2023507973 A JP 2023507973A JP WO2022032004 A5 JPWO2022032004 A5 JP WO2022032004A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025250936A JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061895P | 2020-08-06 | 2020-08-06 | |
| US63/061,895 | 2020-08-06 | ||
| US202063074582P | 2020-09-04 | 2020-09-04 | |
| US63/074,582 | 2020-09-04 | ||
| US202163144657P | 2021-02-02 | 2021-02-02 | |
| US63/144,657 | 2021-02-02 | ||
| PCT/US2021/044801 WO2022032004A2 (en) | 2020-08-06 | 2021-08-05 | Anti-claudin 18.2 multi-specific antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025250936A Division JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023537002A JP2023537002A (ja) | 2023-08-30 |
| JP2023537002A5 JP2023537002A5 (https=) | 2024-08-13 |
| JPWO2022032004A5 true JPWO2022032004A5 (https=) | 2024-08-13 |
| JP7792395B2 JP7792395B2 (ja) | 2025-12-25 |
Family
ID=80117669
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507973A Active JP7792395B2 (ja) | 2020-08-06 | 2021-08-05 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
| JP2025250936A Pending JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025250936A Pending JP2026034608A (ja) | 2020-08-06 | 2025-12-15 | 抗クローディン１８．２多重特異性抗体及びそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230279152A1 (https=) |
| EP (1) | EP4192879A4 (https=) |
| JP (2) | JP7792395B2 (https=) |
| KR (1) | KR20230070203A (https=) |
| WO (2) | WO2022032003A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| WO2021142471A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| JP2025511493A (ja) | 2022-05-31 | 2025-04-16 | エルジー エナジー ソリューション リミテッド | リチウム二次電池用複合固体電解質及びこの製造方法 |
| CN119101162A (zh) * | 2023-06-07 | 2024-12-10 | 江苏奥赛康生物医药有限公司 | 一种抗cldn18_2的抗体及体外诊断试剂盒 |
| CN119487068A (zh) * | 2023-06-08 | 2025-02-18 | 德琪(杭州)生物有限公司 | 抗cldn18.2抗体及其诊断用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436397B1 (en) * | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| SG11201702606TA (en) * | 2014-10-03 | 2017-04-27 | Massachusetts Inst Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| WO2016196343A1 (en) * | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
| JP6768011B2 (ja) * | 2015-06-23 | 2020-10-14 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｃｄ１２３抗体との抗体薬物複合体 |
| SG11202007074PA (en) * | 2018-05-18 | 2020-08-28 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
| CN111867630B (zh) * | 2018-06-17 | 2023-10-13 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| CN112770723B (zh) * | 2018-07-25 | 2024-08-02 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| JOP20210022A1 (ar) * | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| US10522488B1 (en) * | 2018-10-31 | 2019-12-31 | Taiwan Semiconductor Manufacturing Company, Ltd. | Patterning polymer layer to reduce stress |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
-
2021
- 2021-08-05 WO PCT/US2021/044800 patent/WO2022032003A2/en not_active Ceased
- 2021-08-05 US US18/019,728 patent/US20230279152A1/en active Pending
- 2021-08-05 JP JP2023507973A patent/JP7792395B2/ja active Active
- 2021-08-05 EP EP21853256.2A patent/EP4192879A4/en active Pending
- 2021-08-05 WO PCT/US2021/044801 patent/WO2022032004A2/en not_active Ceased
- 2021-08-05 KR KR1020237007877A patent/KR20230070203A/ko active Pending
-
2025
- 2025-12-15 JP JP2025250936A patent/JP2026034608A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paul et al. | Cancer therapy with antibodies | |
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Scott et al. | Antibody therapy of cancer | |
| Cao et al. | Bispecific antibodies as novel bioconjugates | |
| US20210024630A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Zekri et al. | An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers | |
| US11787863B2 (en) | Multi-specific antibodies and methods of making and using thereof | |
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| IL273484B1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
| CN114634569A (zh) | 高亲和力b7-h6抗体和抗体片段 | |
| JP2020523029A5 (https=) | ||
| Lin et al. | The evolution of antibodies into versatile tumor-targeting agents | |
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| JP7592712B2 (ja) | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 | |
| Wang et al. | An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers | |
| JP2021517816A5 (https=) | ||
| Holliger et al. | Engineering antibodies for the clinic | |
| Jachimowicz et al. | Multi-specific antibodies for cancer immunotherapy | |
| JPWO2022032004A5 (https=) | ||
| JP2005510470A (ja) | 二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物 | |
| JPWO2021216972A5 (https=) | ||
| JPWO2020210232A5 (https=) | ||
| JPWO2021046331A5 (https=) | ||
| Elloumi et al. | Monoclonal antibodies as cancer therapeutics |